U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880055) titled 'Shield Post-Approval Study Protocol' on March 11.
Brief Summary: The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC using colonoscopy as the reference method.
Study Start Date: Sept. 01, 2025
Study Type: OBSERVATIONAL
Condition:
Colo-rectal Cancer
Intervention:
DIAGNOSTIC_TEST: Shield Blood Test for colo-rectal cancer Screening
Shield Blood Test for colo-rectal cancer Screening
Recr...